Analysis of 1,000 patients in the MINDACT trial identifies patients with ultra-low risk for distant recurrence. These patients could be candidates for further de-escalation of treatment.
Gene signatures have proven successful in identifying patients with a low risk of distant recurrence who could forego chemotherapy1. Currently, these signatures are included in international treatment guidelines for breast cancer. For the 70-gene signature (MammaPrint), an additional threshold was established within the low-risk category to identify patients with an ultra-low risk of distant recurrence2. In independent cohorts, these patients had excellent breast cancer specific survival at 15 years, suggesting that ultra-low-risk cancers represent indolent disease3.
Dr Josephine Lopes Cardozo (Netherlands Cancer Institute, the Netherlands) presented results of the survival of patients with an ultra-low-risk 70-gene signature who participated in the randomised, phase 3 MINDACT trial (NCT00433589). Of the 6,693 patients enrolled in the MINDACT trial, profiling revealed an ultra-low-risk 70-gene signature in 1,000 patients (15%). Among these patients, 67% were ≥50 years, 81% had tumours <2 cm, 80% were lymph node-negative, 96% had grade 1 or 2 tumours, and 99% were ER-positive.
Of patients with an ultra-low risk according to the 70-gene signature, 741 had a low clinical risk and 259 had a high clinical risk. Systemic therapy was received by 83% of patients (69% endocrine therapy, 14% endocrine therapy plus chemotherapy) and 16% received no adjuvant systemic treatment.
After a median follow-up of 8.7 years, 8-year distant metastasis-free interval in the patients with ultra-low risk was 97.0% (versus 94.5% for patients with low-risk signature and 89.2% for patients with high-risk signature). Breast cancer-specific survival rate at 8 years was 99.6%, 98.2%, and 93.7%, respectively. The difference in distant metastasis-free interval between patients with ultra-low-risk signature and clinical low risk (n=741) versus ultra-low-risk signature and clinical high risk (n=259) was small: 97.6% versus 95.0%.
No difference in breast cancer-specific survival was observed in genomic ultra-low-risk patients by clinical risk: 99.7% versus 99.2%. Distant metastasis-free interval in genomic ultra-low-risk patients who had received no adjuvant systemic treatment was 97.8% versus 97.4% in ultra-low-risk patients who had received adjuvant endocrine systemic therapy and 94.9% in ultra-low-risk patients who had received adjuvant endocrine therapy and chemotherapy.
Based on these results, Dr Lopes Cardoso concluded that “the 70-gene signature MammaPrint can identify early breast cancer patients who have an ultra-low risk for distant recurrence. These patients could be candidate for further de-escalation of treatment, further reducing overtreatment and the risk of side effects.”
1. Piccart M, et al. Lancet Oncol. 2021; 22:476-488.
2. Esserman LJ, et al. JAMA Oncol 2017, 3: 1503-1510.
3. Delahaye LJMJ, et al. BC Res Treat 2017; 164: 461-466.
4. Lopes Cardozo J, et al. Outcome of patients with an ultralow risk 70-gene signature in the MINDACT trial. ASCO 2021 Virtual Meeting, abstract 500.